

Kevin Outterson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8384356/publications.pdf>

Version: 2024-02-01

73
papers

6,128
citations

236833

25
h-index

133188

59
g-index

74
all docs

74
docs citations

74
times ranked

8369
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020. <i>Clinical Infectious Diseases</i> , 2022, 74, 1183-1190.	2.9	15
2	Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can – Now We Need to Start Pulling!. <i>Clinical Infectious Diseases</i> , 2021, 73, e4451-e4453.	2.9	11
3	Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. <i>Clinical Infectious Diseases</i> , 2021, 72, e420-e421.	2.9	10
4	The effect of generic market entry on antibiotic prescriptions in the United States. <i>Nature Communications</i> , 2021, 12, 2937.	5.8	6
5	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. <i>Value in Health</i> , 2021, 24, 1828-1834.	0.1	22
6	Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 488-504.	157.7	65
7	The impact of infections on reimbursement in 92 US hospitals, 2015-2018. <i>American Journal of Infection Control</i> , 2021, 49, 1275-1280.	1.1	1
8	Improving data sharing to increase the efficiency of antibiotic R&D. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 1-2.	21.5	32
9	Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines. <i>Health Affairs</i> , 2021, 40, 1758-1765.	2.5	13
10	The global preclinical antibacterial pipeline. <i>Nature Reviews Microbiology</i> , 2020, 18, 275-285.	13.6	442
11	Antibiotic development – economic, regulatory and societal challenges. <i>Nature Reviews Microbiology</i> , 2020, 18, 267-274.	13.6	218
12	Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy. <i>BMJ Global Health</i> , 2020, 5, e003091.	2.0	47
13	Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. <i>Translational Research</i> , 2020, 220, 182-190.	2.2	27
14	The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e51-e60.	4.6	161
15	Social, cultural and economic aspects of antimicrobial resistance. <i>Bulletin of the World Health Organization</i> , 2020, 98, 823-823A.	1.5	16
16	Designing development programs for non-traditional antibacterial agents. <i>Nature Communications</i> , 2019, 10, 3416.	5.8	46
17	A roadmap for sustainably governing the global antimicrobial commons. <i>Lancet</i> , The, 2019, 394, 1788-1789.	6.3	13
18	A shot in the arm for new antibiotics. <i>Nature Biotechnology</i> , 2019, 37, 1110-1112.	9.4	17

#	ARTICLE	IF	CITATIONS
19	Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 63-65.	0.6	5
20	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 318-327.	4.6	3,672
21	Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. <i>Journal of Pharmaceutical Policy and Practice</i> , 2018, 11, 8.	1.1	20
22	A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 59-65.	0.4	11
23	Introduction and geographic availability of new antibiotics approved between 1999 and 2014. <i>PLoS ONE</i> , 2018, 13, e0205166.	1.1	33
24	The Fight Against Multidrug-Resistant Bacteria. <i>Annals of Internal Medicine</i> , 2017, 166, 79.	2.0	0
25	Innovation in the preclinical antibiotic pipeline. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 744-745.	21.5	10
26	To the G20: incentivising antibacterial research and development. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 799-801.	4.6	31
27	Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	1
28	Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administrationâ€™ Approved Antibiotics, 2010â€™2015. <i>Annals of Internal Medicine</i> , 2016, 165, 363.	2.0	81
29	Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. <i>Health Affairs</i> , 2016, 35, 784-790.	2.5	19
30	Accelerating global innovation to address antibacterial resistance: introducing CARB-X. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 589-590.	21.5	45
31	International cooperation to improve access to and sustain effectiveness of antimicrobials. <i>Lancet</i> , The, 2016, 387, 296-307.	6.3	114
32	Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 500-505.	4.6	86
33	Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. <i>PLoS Medicine</i> , 2016, 13, e1002043.	3.9	54
34	What Will it Take to Address the Global Threat of Antibiotic Resistance?. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 6-11.	0.4	19
35	What Will it Take to Address the Global Threat of Antibiotic Resistance?. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 363-368.	0.4	36
36	Antibiotic research and development: business as usual?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1604-7.	1.3	60

#	ARTICLE	IF	CITATIONS
37	An international legal framework to address antimicrobial resistance. Bulletin of the World Health Organization, 2015, 93, 66-66.	1.5	80
38	Repairing The Broken Market For Antibiotic Innovation. Health Affairs, 2015, 34, 277-285.	2.5	96
39	Clinical Trial Transparency “ Antidote to Weaker Off-Label-Promotion Rules?. New England Journal of Medicine, 2014, 371, 1-3.	13.9	16
40	Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980–2009. Journal of Law, Medicine and Ethics, 2013, 41, 688-696.	0.4	38
41	Punishing Health Care Fraud “ Is the GSK Settlement Sufficient?. New England Journal of Medicine, 2012, 367, 1082-1085.	13.9	25
42	Regulating Compounding Pharmacies after NECC. New England Journal of Medicine, 2012, 367, 1969-1972.	13.9	47
43	Germ Shed Management in the United States. , 2012, , 163-181.		2
44	Smoking and the First Amendment. New England Journal of Medicine, 2011, 365, 2351-2353.	13.9	6
45	Higher First Amendment Hurdles for Public Health Regulation. New England Journal of Medicine, 2011, 365, e13.	13.9	9
46	Poverty Tourism, Justice, and Policy. Public Integrity, 2011, 14, 39-50.	0.8	6
47	Poverty tourism and the problem of consent. Journal of Global Ethics, 2011, 7, 337-348.	0.1	26
48	Improving antibiotic markets for long-term sustainability. Yale Journal of Health Policy, Law, and Ethics, 2011, 11, 101-67.	1.5	16
49	Questions about the 10 – 20 Initiative. Clinical Infectious Diseases, 2010, 51, 751-752.	2.9	6
50	The Ethics of Poverty Tourism. Environmental Philosophy, 2010, 7, 93-114.	0.1	14
51	Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals. Health Affairs, 2010, 29, 1689-1696.	2.5	55
52	Disease-based Limitations on Compulsory Licenses Under Articles 31 and 31bis. , 2010, , .		4
53	Foreword “ Will HPV Vaccines Prevent Cervical Cancers Among Poor Women of Color?: Global Health Policy at the Intersection of Human Rights and Intellectual Property Law. American Journal of Law and Medicine, 2009, 35, 247-252.	0.5	6
54	How Medicare Could Get Better Prices On Prescription Drugs. Health Affairs, 2009, 28, w832-w841.	2.5	19

#	ARTICLE	IF	CITATIONS
55	Pharmaceutical Innovation: Law & the Public's Health. <i>Journal of Law, Medicine and Ethics</i> , 2009, 37, 173-175.	0.4	3
56	Antibiotic resistance and antibiotic development – Author's reply. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 212-214.	4.6	6
57	Market-Based Licensing For HPV Vaccines In Developing Countries. <i>Health Affairs</i> , 2008, 27, 130-139.	2.5	23
58	Should Access to Medicines and TRIPS Flexibilities Be Limited to Specific Diseases?. <i>American Journal of Law and Medicine</i> , 2008, 34, 279-301.	0.5	23
59	Will longer antimicrobial patents improve global public health?. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 559-566.	4.6	54
60	Patent Buy-Outs for Global Disease Innovations for Low-and Middle-Income Countries. <i>American Journal of Law and Medicine</i> , 2006, 32, 159-173.	0.5	17
61	Agony in the Antipodes: The generic drug provisions of the Australia-USA Free Trade Agreement. <i>Journal of Generic Medicines</i> , 2005, 2, 316-326.	0.0	9
62	The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law. <i>University of Pittsburgh Law Review</i> , 2005, 67, .	0.0	22
63	Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. <i>Yale Journal of Health Policy, Law, and Ethics</i> , 2005, 5, 193-291.	1.5	26
64	GP corporatisation: lessons to be learned. <i>Medical Journal of Australia</i> , 2001, 175, 426-427.	0.8	1
65	The Ethics of Poverty Tourism. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
66	Combating Antibiotic Resistance Through the Health Impact Fund. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
67	Testimony of Kevin Outterson (Boston University School of Law) to the House Energy and Commerce Committee, September 19, 2014. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
68	Resolving Dysfunctional Pharmaceutical Arbitrage and Counterfeiting through the Proposed Hubbard-Love R&D Treaty. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
69	Nonrival Access to Pharmaceutical Knowledge. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
70	US Senate Health, Education, Labor, & Pensions Committee Hearing on Drug Importation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
71	Access to Global Disease Innovation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
72	William H. Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc., et al. - Amicus Brief in Support of Petitioners. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
73	Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach. SSRN Electronic Journal, 0, , .	0.4	0